Smart materials change properties in response to specific DNA sequences; could be used in a variety of devices.
The CRISPR genome-editing system is best-known for its potential to correct disease-causing mutations and add new genes into living cells. Now, a team from MIT and Harvard University has deployed CRISPR for a completely different purpose: creating novel materials, such as gels, that can change their properties when they encounter specific DNA sequences.
The researchers showed they could use CRISPR to control electronic circuits and microfluidic devices, and to release drugs, proteins, or living cells from gels. Such materials could be used to create diagnostic devices for diseases such as Ebola, or to deliver treatments for diseases such as irritable bowel disease.
“This study serves as a nice starting point for showing how CRISPR can be utilized in materials science for a really wide range of applications,” says James Collins, the Termeer Professor of Medical Engineering and Science in MIT’s Institute for Medical Engineering and Science (IMES) and Department of Biological Engineering, and the senior author of the study.
The lead authors of the study, which appears in the Aug. 22 online edition of Science, are MIT graduate students Max Atti English, Luis Soenksen, and Raphael Gayet, and postdoc Helena de Puig.
CRISPR is based on DNA-cutting proteins called Cas enzymes, which bind to short RNA guides that direct them to specific areas of the genome. Cas cuts DNA in those locations, deleting a gene or allowing new genetic sequences to be introduced.
Over the past several years, much research has been devoted to developing CRISPR as a gene-editing tool for treating disease by cutting out or repairing faulty genes. The MIT and Harvard team set out to adapt it for creating materials that could respond to external cues such as the presence of a certain sequence of DNA.
For this work, they used an enzyme known as Cas12a, which can be programmed to bind to specific sequences of double-stranded DNA by simply changing the guide RNA sequence that is given along with the enzyme. Once Cas12a encounters a target DNA sequence, also called a trigger, it cleaves the double-stranded DNA and transforms into an enzyme that can slice any single-stranded DNA it encounters.
“By incorporating DNA into materials, you can use this enzyme to control the properties of the materials in response to a specific biological cue in the environment,” English says.
The researchers took advantage of this to design gels that incorporate single-stranded DNA in key functional or structural roles. In one example, they created a gel made of polyethylene glycol (PEG) and used DNA to anchor enzymes or other large biomolecules to the gel. When activated by a trigger sequence, Cas12a cuts the DNA anchors, releasing the payload.
That type of gel could be useful for releasing therapeutic compounds such as drugs or growth factors, the researchers say. In another example, they created an acrylamide gel in which single-stranded DNA forms an integral part of the gel structure. In that case, when Cas12a is activated by the trigger, the entire gel breaks down, enabling the release of larger cargoes such as cells or nanoparticles.
“In that context, we consider the single-stranded DNA as a structural scaffold,” Gayet says. “The enzyme is able to catalyze the cleavage of the single-stranded DNA, which acts as a structural linker, and release all of those molecules.”
The researchers are now exploring the possibility of using this approach to deliver engineered bacterial cells to help treat gastrointestinal diseases.
The researchers also created two CRISPR-controlled diagnostic devices, one based on an electronic circuit and the other on a microfluidic chip.
To create the electronic circuit, the researchers designed a gel that includes single-stranded DNA and a material called carbon black, which conducts electricity. When attached to the surface of an electrode, this conductive gel allows electrical current to flow. However, if Cas12a is activated by a trigger sequence, such as a strand of viral DNA from a blood sample, the gel becomes detached from the electrode and current stops flowing.
For their microfluidic sensor, the researchers created a DNA-containing gel that acts as a valve that controls the flow of a solution through the microfluidic channel. If the solution contains a blood sample with a target DNA sequence, the gel breaks down, turning off the valve, and the solution stops flowing. This microfluidic sensor can be connected to an RFID chip, allowing it to wirelessly transmit the results of the test.
“A health care worker can be monitoring dozens of patients, and the presence or absence of the Ebola trigger will automatically relay a binary signal,” Soenksen says.
While the researchers used fluid samples containing Ebola virus RNA to test this approach, it could also be adapted to detect other infectious diseases, as well as cancer cells circulating in a patient’s bloodstream.
Philip LeDuc, a professor of mechanical engineering at Carnegie Mellon University, describes the work as “tremendously creative.”
“This is a very non-obvious intersection of two different fields, and the influence of this work will be far-reaching,” says LeDuc, who was not involved in the study. “This transdisciplinary work may enable an entire new generation of approaches for applications from building artificial organs to improving the environment.”
Learn more: Using CRISPR to program gels with new functions
The Latest on: CRISPR
via Google News
The Latest on: CRISPR
- Animal Model Market Driven by Developments in Pharmaceutical and CRISPR Genetic Research, Opines Fact.MRon April 14, 2021 at 6:39 am
Leading research organizations are investing increasingly in the use of advanced animal models for CRISPR and microinjection applications for long-term growth opportunities. NEW YORK, NY / ACCESSWIRE ...
- It takes two to Tango: The biotech using CRISPR to discover new cancer gene targets rides a $353M SPAC deal to Nasdaqon April 14, 2021 at 5:30 am
Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here. The latest biotech-SPAC deal has arrived, and it's dancing its way to Nasdaq to the tune of several ...
- How Much Of CRISPR Therapeutics AG (NASDAQ:CRSP) Do Institutions Own?on April 13, 2021 at 2:24 am
The big shareholder groups in CRISPR Therapeutics AG (NASDAQ:CRSP) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders ...
- CRISPR Therapies Pipeline Insights 2021: Analysis of Key Companies, Emerging Therapies, Recent Happenings and Futuristic Trendson April 12, 2021 at 5:31 pm
The leading gene-editing companies looking at commercializing CRISPR-based therapeutics are CRISPR Therapeutics, Intellia Therapeutics, and Editas Medicine. CRISPR Therapeutics has the largest market ...
- New CRISPR Breakthrough Can Turn Genes On And Off With Easeon April 12, 2021 at 9:38 am
CRISPR-Cas9, a revolutionary genetic editing tool that allows scientists to change the DNA code of an organism, has quickly become one of the most importan ...
- Researchers call for greater awareness of unintended consequences of CRISPR gene editingon April 12, 2021 at 5:10 am
Researchers at the Francis Crick Institute have revealed that CRISPR-Cas9 genome editing can lead to unintended mutations at the targeted section of DNA in early human embryos. The work highlights the ...
- Chromothripsis as an on-target consequence of CRISPR–Cas9 genome editingon April 11, 2021 at 5:00 pm
Here, using model cells and single-cell whole-genome sequencing, as well as by editing at a clinically relevant locus in clinically relevant cells, we show that CRISPR–Cas9 editing generates ...
- CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Functionon April 10, 2021 at 5:31 am
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced preclinical data from the Company’s ...
- New, reversible CRISPR method can control gene expression while leaving underlying DNA sequence unchangedon April 9, 2021 at 8:00 am
Over the past decade, the CRISPR-Cas9 gene editing system has revolutionized genetic engineering, allowing scientists to make targeted changes to organisms' DNA. While the system could potentially be ...
- An improved biolistic delivery and analysis method for evaluation of DNA and CRISPR-Cas delivery efficacy in plant tissueon April 8, 2021 at 12:43 pm
In addition, the same approach is applied to test the efficacy of multiple gRNAs for CRISPR-Cas9-mediated gene editing. The novel combination of the bombardment device and analysis method allows ...
via Bing News